E-viri
PDF
Recenzirano
Odprti dostop
-
Wijnsma, Kioa Lente; ter Heine, Rob; Moes, Dirk Jan A. R.; Langemeijer, Saskia; Schols, Saskia E. M.; Volokhina, Elena. B.; van den Heuvel, Lambertus P.; Wetzels, Jack F. M.; van de Kar, Nicole C. A. J.; Brüggemann, Roger J.
Clinical pharmacokinetics, 07/2019, Letnik: 58, Številka: 7Journal Article
Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.
